Bayer ‘Outperforming’ Market As Turnaround Plan Bears Fruit
Bayer says its Consumer Health sales grew at twice the rate of the market in Q3, thanks to a number of operational changes instituted by business head Heiko Schipper back in 2018.
You may also be interested in...
Patrick Lockwood-Taylor starts as president/CEO on 30 June, succeeding Murray Kessler as Perrigo awaits FDA decision on subsidiary HRA’s proposal for first US OTC sales of daily oral contraceptive. He’s moving from president of Bayer AG’s US business and regional president, consumer health North America.
Bayer led a $12m investment in Edifice Health, which plans to launch an OTC test kit to measure “inflammatory age” to help prevent chronic diseases. Consumer health R&D head Dave Evendon-Challis says the investment is in line with focus on deals for “big innovation jumps” in prevention.
Bayer stepped up its Consumer Health innovation efforts in 2020 in line with its turnaround plan for the business, and now has more than 100 projects in development.